Ori Biotech has secured £7.2m funding and appointed a new CEO.
The London BioTech firm intends to bring its cell and gene therapy manufacturing platform to market with the investment from a syndicate of UK investors including Amadeus Capital Partners, Delin Ventures and Kindred Capital.
Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, Ori has designed a bespoke platform to specifically address the unique requirements of the new generation of personalised, living medicines.
Jason C. Foster, managing director at Health Equity Consulting and an experienced non-executive director, is the newly appointed CEO of Ori Biotech.
“The successful financing underscores the potential of the Ori platform to fully automate cell and gene therapy manufacturing to increase throughput, improve quality and decrease costs,” he said.
“We look forward to collaborating with best-in-class suppliers, service providers and therapeutics developers to create next generation manufacturing solutions.
“We appreciate the support from our investors, and I am honoured to join a company that has the potential to positively impact millions of lives by enabling patient access to these lifesaving treatments.”